These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 15113848)

  • 41. NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy.
    Mirza NR; Larsen JS; Mathiasen C; Jacobsen TA; Munro G; Erichsen HK; Nielsen AN; Troelsen KB; Nielsen EØ; Ahring PK
    J Pharmacol Exp Ther; 2008 Dec; 327(3):954-68. PubMed ID: 18791063
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of chalcones--a flavonoid subclass, for, their anxiolytic effects in rats using elevated plus maze and open field behaviour tests.
    Jamal H; Ansari WH; Rizvi SJ
    Fundam Clin Pharmacol; 2008 Dec; 22(6):673-81. PubMed ID: 19049672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.
    Martin JR; Bös M; Jenck F; Moreau J; Mutel V; Sleight AJ; Wichmann J; Andrews JS; Berendsen HH; Broekkamp CL; Ruigt GS; Köhler C; Delft AM
    J Pharmacol Exp Ther; 1998 Aug; 286(2):913-24. PubMed ID: 9694950
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors.
    Malherbe P; Masciadri R; Norcross RD; Knoflach F; Kratzeisen C; Zenner MT; Kolb Y; Marcuz A; Huwyler J; Nakagawa T; Porter RH; Thomas AW; Wettstein JG; Sleight AJ; Spooren W; Prinssen EP
    Br J Pharmacol; 2008 Jun; 154(4):797-811. PubMed ID: 18536733
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning.
    Jacob W; Gravius A; Pietraszek M; Nagel J; Belozertseva I; Shekunova E; Malyshkin A; Greco S; Barberi C; Danysz W
    Neuropharmacology; 2009 Aug; 57(2):97-108. PubMed ID: 19426746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The GABA
    Olianas MC; Dedoni S; Onali P
    Eur J Pharmacol; 2017 Jan; 794():135-146. PubMed ID: 27876620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.
    Galici R; Jones CK; Hemstapat K; Nong Y; Echemendia NG; Williams LC; de Paulis T; Conn PJ
    J Pharmacol Exp Ther; 2006 Jul; 318(1):173-85. PubMed ID: 16608916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 6,2'-Dihydroxyflavone, a subtype-selective partial inverse agonist of GABAA receptor benzodiazepine site.
    Wang F; Xu Z; Yuen CT; Chow CY; Lui YL; Tsang SY; Xue H
    Neuropharmacology; 2007 Sep; 53(4):574-82. PubMed ID: 17681556
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The NK1 receptor antagonist NKP608 lacks anxiolytic-like activity in Swiss-Webster mice exposed to the elevated plus-maze.
    Rodgers RJ; Gentsch C; Hoyer D; Bryant E; Green AJ; Kolokotroni KZ; Martin JL
    Behav Brain Res; 2004 Sep; 154(1):183-92. PubMed ID: 15302124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of the GABA(B) receptor in alcohol-seeking and drinking behavior.
    Maccioni P; Colombo G
    Alcohol; 2009 Nov; 43(7):555-8. PubMed ID: 19913200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ro 19-8022, a nonbenzodiazepine partial agonist at benzodiazepine receptors: neuropharmacological profile of a potential anxiolytic.
    Jenck F; Moreau JL; Bonetti EP; Martin JR; Haefely WE
    J Pharmacol Exp Ther; 1992 Sep; 262(3):1121-7. PubMed ID: 1356150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The anxiolytic-like effects of Aloysia polystachya (Griseb.) Moldenke (Verbenaceae) in mice.
    Hellión-Ibarrola MC; Ibarrola DA; Montalbetti Y; Kennedy ML; Heinichen O; Campuzano M; Tortoriello J; Fernández S; Wasowski C; Marder M; De Lima TC; Mora S
    J Ethnopharmacol; 2006 May; 105(3):400-8. PubMed ID: 16386395
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Altered response to benzodiazepine anxiolytics in mice lacking GABA B(1) receptors.
    Mombereau C; Kaupmann K; van der Putten H; Cryan JF
    Eur J Pharmacol; 2004 Aug; 497(1):119-20. PubMed ID: 15321743
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of CA3 GABA
    Zarrabian S; Nasehi M; Farrahizadeh M; Zarrindast MR
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):515-524. PubMed ID: 28800869
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.
    Pacey LK; Tharmalingam S; Hampson DR
    J Pharmacol Exp Ther; 2011 Sep; 338(3):897-905. PubMed ID: 21636656
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats.
    Knoll AT; Meloni EG; Thomas JB; Carroll FI; Carlezon WA
    J Pharmacol Exp Ther; 2007 Dec; 323(3):838-45. PubMed ID: 17823306
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems.
    Stachowicz K; Kłodzińska A; Palucha-Poniewiera A; Schann S; Neuville P; Pilc A
    Neuropharmacology; 2009 Sep; 57(3):227-34. PubMed ID: 19539634
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
    Satow A; Maehara S; Ise S; Hikichi H; Fukushima M; Suzuki G; Kimura T; Tanak T; Ito S; Kawamoto H; Ohta H
    J Pharmacol Exp Ther; 2008 Aug; 326(2):577-86. PubMed ID: 18487514
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Naloxone and baclofen attenuate ethanol's locomotor-activating effects in preweanling Sprague-Dawley rats.
    Arias C; Mlewski EC; Molina JC; Spear NE
    Behav Neurosci; 2009 Feb; 123(1):172-80. PubMed ID: 19170442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GABAB receptor-positive modulation-induced blockade of the rewarding properties of nicotine is associated with a reduction in nucleus accumbens DeltaFosB accumulation.
    Mombereau C; Lhuillier L; Kaupmann K; Cryan JF
    J Pharmacol Exp Ther; 2007 Apr; 321(1):172-7. PubMed ID: 17215447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.